TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that pursuant to an agreement with a collaboration partner entered February 22, 2017, it has agreed to co-develop two more niche injectable products that will be sold on the TruPharma label. The products and the partner are confidential pending FDA approval of the ANDAs. TruPharma expects the products under development will be submitted to FDA in the first half of 2018.